reviewJournal of Microbiology Immunology and InfectionApr 4, 2020GOLD OA

Treatment options for COVID-19: The reality and challenges

SJShio‐Shin JeanPLPing‐Ing LeePHPo‐Ren Hsueh

Taipei Medical University · Wan Fang Hospital · +1 more institution

PubMed
Indexed incrossrefdoajpubmed

Abstract

An outbreak related to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was first reported in Wuhan, China in December 2019. An extremely high potential for dissemination resulted in the global coronavirus disease 2019 (COVID-19) pandemic in 2020. Despite the worsening trends of COVID-19, no drugs are validated to have significant efficacy in clinical treatment of COVID-19 patients in large-scale studies. Remdesivir is considered the most promising antiviral agent; it works by inhibiting the activity of RNA-dependent RNA polymerase (RdRp). A large-scale study investigating the clinical efficacy of remdesivir (200 mg on day 1, followed by 100 mg once daily) is on-going. The other excellent…

Citation impact

532
total citations
FWCI
12.84
Percentile
100%
References
68
Citations per year

Authors

3

Topics & keywords

Topics
Keywords
  • Favipiravir
  • Ritonavir
  • Lopinavir
  • Medicine
  • Pharmacology
  • Hydroxychloroquine
  • Azithromycin
  • Virology
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.

Funding